BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24843320)

  • 1. Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
    Saito T; Chiba T; Suzuki E; Shinozaki M; Goto N; Kanogawa N; Motoyama T; Ogasawara S; Ooka Y; Tawada A; Kanda T; Miyazaki M; Yokosuka O
    Int J Med Sci; 2014; 11(7):707-12. PubMed ID: 24843320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
    Hagihara H; Nouso K; Kobayashi Y; Iwasaki Y; Nakamura S; Kuwaki K; Toshimori J; Miyatake H; Ohnishi H; Shiraha H; Yamamoto K
    Int J Clin Oncol; 2011 Jun; 16(3):210-20. PubMed ID: 21152943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Sustained Virological Response to Interferon Therapy on Recurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Shinkawa H; Hasegawa K; Arita J; Akamatsu N; Kaneko J; Sakamoto Y; Kokudo N
    Ann Surg Oncol; 2017 Oct; 24(11):3196-3202. PubMed ID: 28707053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.
    Miyatake H; Kobayashi Y; Iwasaki Y; Nakamura S; Ohnishi H; Kuwaki K; Toshimori J; Hagihara H; Nouso K; Yamamoto K
    Dig Dis Sci; 2012 Apr; 57(4):1092-101. PubMed ID: 21989822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma.
    Tsujita E; Maeda T; Kayashima H; Harada N; Tsutsui S; Matsuda H; Kinjo N; Ikeda Y; Morita M; Ishida T
    Hepatogastroenterology; 2015; 62(137):157-63. PubMed ID: 25911888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    Mashiba T; Joko K; Kurosaki M; Ochi H; Osaki Y; Kojima Y; Nakata R; Goto T; Takehiro A; Kimura H; Mitsuda A; Kawanami C; Uchida Y; Ogawa C; Kusakabe A; Narita R; Ide Y; Abe T; Tsuji K; Kitamura T; Okada K; Sohda T; Shigeno M; Satou T; Izumi N
    PLoS One; 2018; 13(4):e0194704. PubMed ID: 29659591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.
    Petta S; Cabibbo G; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Tovoli F; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Felder M; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Boccaccio V; Craxì A; Bruno S; Trevisani F; Cammà C;
    Aliment Pharmacol Ther; 2017 Jan; 45(1):160-168. PubMed ID: 27790734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation.
    Ryu T; Takami Y; Wada Y; Tateishi M; Matsushima H; Yoshitomi M; Mikagi K; Saitsu H
    Hepatol Int; 2018 Mar; 12(2):149-157. PubMed ID: 29488056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    Motoyama H; Tamori A; Kubo S; Uchida-Kobayashi S; Takemura S; Tanaka S; Ohfuji S; Teranishi Y; Kozuka R; Kawamura E; Hagihara A; Morikawa H; Enomoto M; Murakami Y; Kawada N
    PLoS One; 2018; 13(3):e0194163. PubMed ID: 29534101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
    Ann Surg Oncol; 2019 Dec; 26(13):4566-4575. PubMed ID: 31602577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor.
    Kanogawa N; Ogasawara S; Chiba T; Saito T; Motoyama T; Suzuki E; Ooka Y; Tawada A; Kanda T; Mikami S; Azemoto R; Kaiho T; Shinozaki M; Ohtsuka M; Miyazaki M; Yokosuka O
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1197-204. PubMed ID: 25682720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C.
    Tsujita E; Yamashita Y; Takeishi K; Maeda T; Takaki S; Mori N; Aisaka Y; Furukawa Y; Shirabe K; Ishida T; Maehara Y
    Hepatogastroenterology; 2013; 60(128):2048-54. PubMed ID: 24088310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection.
    Nirei K; Kanda T; Nakamura H; Matsuoka S; Takayama T; Sugitani M; Moriyama M
    Int J Med Sci; 2018; 15(5):466-474. PubMed ID: 29559835
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
    Sou FM; Wu CK; Chang KC; Lu SN; Wang JH; Hung CH; Chen CH; Kee KM; Yen YH; Lin MT; Tsai MC; Hu TH
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):504-513. PubMed ID: 30527565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
    Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
    [No Abstract]   [Full Text] [Related]  

  • 18. Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.
    Shirabe K; Sugimachi K; Harada N; Kayashima H; Maeda T; Tsujita E; Minagawa R; Kajiyama K; Yoshiya S; Maehara Y
    Anticancer Res; 2015 Dec; 35(12):6963-9. PubMed ID: 26637923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.
    Tanimoto Y; Tashiro H; Aikata H; Amano H; Oshita A; Kobayashi T; Kuroda S; Tazawa H; Takahashi S; Itamoto T; Chayama K; Ohdan H
    Ann Surg Oncol; 2012 Feb; 19(2):418-25. PubMed ID: 21710324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.